Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Melanoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibromatosis 1 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Specimen Handling 40Biopsy 32Magnetic Resonance Spectroscopy 26pembrolizumab 20Nivolumab 10trastuzumab deruxtecan 9Paclitaxel 9Carboplatin 9Radiosurgery 7Irinotecan 7Gemcitabine 7X-Rays 6Pemetrexed 6Leucovorin 6Ipilimumab 6Fulvestrant 6Fluorouracil 6Cetuximab 6Bevacizumab 6palbociclib 5Taxes 5Oxaliplatin 5Cisplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Letrozole 4CTLA-4 Antigen 4ribociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × omipalisib × 30 days × Clear all
NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡